Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Wolber

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 2, 2020
Mismatch repair deficiency and prognostic significance in patients with low-risk endometrioid endometrial cancersSoyoun Rachel Kim, Annick Pina, Arianne Albert, et al.
Histopathology|November 3, 2019
Should you repeat mismatch repair testing in cases of tumour recurrence? An evaluation of repeat mismatch repair testing by the use of immunohistochemistry in recurrent tumours of the gastrointestinal and gynaecological tractsJohn J Aird, Michael J Steel, Christine Chow, et al.
The Journal of Molecular Diagnostics : JMD|January 15, 2016
Quantitative Detection and Resolution of BRAF V600 Status in Colorectal Cancer Using Droplet Digital PCR and a Novel Wild-Type Negative AssayRoza Bidshahri, Dean Attali, Kareem Fakhfakh, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|June 27, 2019
Immunohistochemistry Critical Assay Performance Controls (ICAPC) Reduce Interobserver Variability in the Interpretation of BRAFV600E ImmunohistochemistryNadia S Gale, Steve E Kalloger, Ellen Cai, et al.
Histopathology|July 13, 2016
Basal biomarkers nestin and INPP4b identify intrinsic subtypes accurately in breast cancers that are weakly positive for oestrogen receptorKarama Asleh-Aburaya, Brandon S Sheffield, Zuzana Kos, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 20, 2020
Targeted RNA expression profiling identifies high-grade endometrial stromal sarcoma as a clinically relevant molecular subtype of uterine sarcomaAmir Momeni-Boroujeni, Nissreen Mohammad, Robert Wolber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2020
Population-based Screening for <i>BRAF</i> <sup>V600E</sup> in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor PrognosisJenny E Chu, Benny Johnson, Laveniya Kugathasan, et al.
Cancer Medicine|July 24, 2020
Evaluating the impact of universal Lynch syndrome screening in a publicly funded healthcare systemPetra W C Lee, Angela C Bedard, Setareh Samimi, et al.
Breast Cancer Research and Treatment|February 6, 2016
Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptorBrandon S Sheffield, Zuzana Kos, Karama Asleh-Aburaya, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|April 14, 2009
Implementation of a Canadian external quality assurance program for breast cancer biomarkers: an initiative of Canadian Quality Control in immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/ImmunohistochemistryJefferson Terry, Emina Emilia Torlakovic, John Garratt, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 2, 2020
Mismatch repair deficiency and prognostic significance in patients with low-risk endometrioid endometrial cancersSoyoun Rachel Kim, Annick Pina, Arianne Albert, et al.
Histopathology|November 3, 2019
Should you repeat mismatch repair testing in cases of tumour recurrence? An evaluation of repeat mismatch repair testing by the use of immunohistochemistry in recurrent tumours of the gastrointestinal and gynaecological tractsJohn J Aird, Michael J Steel, Christine Chow, et al.
The Journal of Molecular Diagnostics : JMD|January 15, 2016
Quantitative Detection and Resolution of BRAF V600 Status in Colorectal Cancer Using Droplet Digital PCR and a Novel Wild-Type Negative AssayRoza Bidshahri, Dean Attali, Kareem Fakhfakh, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|June 27, 2019
Immunohistochemistry Critical Assay Performance Controls (ICAPC) Reduce Interobserver Variability in the Interpretation of BRAFV600E ImmunohistochemistryNadia S Gale, Steve E Kalloger, Ellen Cai, et al.
Histopathology|July 13, 2016
Basal biomarkers nestin and INPP4b identify intrinsic subtypes accurately in breast cancers that are weakly positive for oestrogen receptorKarama Asleh-Aburaya, Brandon S Sheffield, Zuzana Kos, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 20, 2020
Targeted RNA expression profiling identifies high-grade endometrial stromal sarcoma as a clinically relevant molecular subtype of uterine sarcomaAmir Momeni-Boroujeni, Nissreen Mohammad, Robert Wolber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2020
Population-based Screening for <i>BRAF</i> <sup>V600E</sup> in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor PrognosisJenny E Chu, Benny Johnson, Laveniya Kugathasan, et al.
Cancer Medicine|July 24, 2020
Evaluating the impact of universal Lynch syndrome screening in a publicly funded healthcare systemPetra W C Lee, Angela C Bedard, Setareh Samimi, et al.
Breast Cancer Research and Treatment|February 6, 2016
Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptorBrandon S Sheffield, Zuzana Kos, Karama Asleh-Aburaya, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|April 14, 2009
Implementation of a Canadian external quality assurance program for breast cancer biomarkers: an initiative of Canadian Quality Control in immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/ImmunohistochemistryJefferson Terry, Emina Emilia Torlakovic, John Garratt, et al.
Pageof 2